Saturday 17 October 2026
Export AKTS’s income statement to Excel — free account
Aktis Oncology, Inc.
AKTS Healthcare Biotechnology
Aktis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.5 million, up 336.9% from fiscal 2024. Insiders bought in the last twelve months.
15.06
0.95
−5.93%
Follow AKTS
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
+3 more quarters Free account |
P/S ratio |
184.52 | 0.00 | — | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(86.58) | (35.89) | — | (0.28) | |
P/B ratio |
3.68 | 1.72 | — | 0.00 | |
Price to Tangible BV |
3.68 | 1.72 | — | 0.00 | |
EV/Sales |
130.97 | 0.00 | — | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(10.11) | (2.72) | — | 2.51 | |
EV/FCF |
(9.08) | (2.42) | — | 2.11 | |
Quick Ratio |
16.10 | 19.29 | 7.26 | — | |
Current Ratio |
16.33 | 19.49 | 7.37 | — | |
Net Debt/EBITDA |
17.81 | 23.84 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.85 | 1.32 | 0.00 | 0.90 | |
Capex/Depreciation |
8.19 | (15.07) | 4.18 | 2.01 | |
Research and Development Expense of Revenue |
747.04% | 620.89% | — | 1,163.52% | |
Selling, General and Administrative Expense of Revenue |
206.94% | 182.74% | — | 245.85% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
95.21% | 93.65% | — | 94.82% | |
Graham Net Nets |
0.25 | 0.54 | — | 8.44 | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(129.71%) | (129.71%) | — | (129.71%) | |
Free Cash Flow Yield |
(7.82%) | (15.74%) | — | (546.91%) | |
Revenue per Share |
0.06 | 0.07 | — | 1.98 | |
Operating CF per Share |
(0.37) | (0.50) | 0.00 | (20.04) | |
Capex per Share |
(0.02) | (0.04) | 0.00 | (1.90) | |
Free Cash Flow per Share |
(0.40) | (0.54) | 0.00 | (21.94) | |
Cash per Share |
9.35 | 11.07 | 0.00 | 0.00 | |
Shareholders Equity per Share |
8.77 | 10.41 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
8.77 | 10.41 | 0.00 | 0.00 | |
Free Cash Flow |
(21.85) | (26.10) | (73.71) | (17.71) | |
Working Capital |
492.41 | 516.03 | 199.07 | — | |
Capital Expenditures |
(1.26) | (1.85) | (9.58) | (1.53) | |
Net Current Asset Value |
451.78 | 473.25 | 152.69 | 0.00 | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.37 | 0.57 | 0.00 | 0.96 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Payables |
1.75 | — | — | — | |
Average Assets |
339.98 | 451.49 | 193.62 | — | |
Average Common Equity |
219.27 | — | — | — |
Columns are period end dates